Media Thread, page-5358

Had a closer re-watch of Leslie's interview with Proactive Investors yesterday. Lots of announcements and catalysts to come during 2022.

Good sleuthing @FreedomInvestor, I tried playing the clip backwards, and got some other stuff out of it ...


Q. Imugene receiving ethics approval for your Phase 2 HER-VAXX trial. Clearly a milestone, tell us a bit more about it.
A. It's a Phase 2 study in combination with Pembrolizumab, better known as KEYTRUDA. This is one of many combinations HER-VAXX is going into and as a company we have lots of combinations happening, but we're just delighted that the site opened ahead of schedule and that we can actually obtain Pembrolizumab off the shelf expeditiously, and we can start dosing patients.

Clip Backwards:
"Hey Andrew, yeah I know some people thought that HER-Vaxx might be a standalone therapy or replace Herceptin in combination with chemo, and yeah, I know its taken nine YEARS to come to the realisation that it won't, and at best will be an adjunct to existing therapies some years from now, but we have opened a site WEEKS ahead of schedule. Now opening a site before we get through the several lines of committees that we need to before we can actually start the trial may seem irrelevant, but my PR team assured me that getting the words "ahead of schedule" into this paid interview was the most important thing."


Q. When can you start dosing patients?
A. We still have to go through several lines of committees but the fact that we can just buy the drug Pembrolizumab off the shelf really helps expedite it...I'm moving the team as fast as they can go.

Clip Backwards:
You know Andrew, back in March I released a Price Sensitive announcement about our collaboration with Merck via its supply of Pembrolizumab. Unfortunately some people viewed this as a positive Price Sensitive announcement. Granted I may have confused things by mentioning that "this collaboration with MSD is significant for our company as it provides theopportunity to optimize and enhance our formulations" and in subsequent interviews when I mentioned how rare it is for BP to supply its products to small biotechs like IMU, and how it was going to save us millions of dollars, but I assure you, I meant the announcement was negatively Price Sensitive.

Anyway, the great news is that Merck terminated this arrangement! How good is that! Now we can buy our own and we don't have to worry about the pesky optimisation and enhancement of our formulations! Hence the Price Sensitive announcement last week, which was definitely a positive.
So positive in fact that the ASX thought I was being overly coy, by not making it more explicit, so they got me to reinforce how positive it really was!


Q. As you said this is one of a number of combinations studies, any updates on the others?
A. Delighted to announce here soon, Vaxinia, that's our parental CF33 virus going into the clinic. There's actually several patients being screened atm, so we've got, [that] (eg trial updates) coming very soon.

CHECKVacc is already in cohort 2 and CHECKVacc has the CF33 with PDL1-transgene, that first cohort of patients is producing some very interesting data and I can't wait to publish on that here soon.

Clip Backwards:
I've copped some criticism for the way in which I drop subtle hints (like "interesting data", "full dance cards" etc ..) in paid-for, promotional interviews like this one with you Andrew, and its lead some investors to draw positive conclusions that haven't been supported by the science. But the strategy of not providing enough clear information in ASX announcements, while dropping overly positive hints in these interviews has been working a treat ... for someone ... I'm sure ...


We've got PD1-VAXX, the non-small lung study that will be combining with tenzentricatazamulab. Now, we already saw some complete responders, as well as some stable disease and PRs in the monotherapy dose escalation. I just am out of my skin excited about that combination, so [that's] (eg data announcement) coming very soon.

We have onCARlytics our CF33 that shuttles up the CD19 flags. Everyone knows we are in partnership with Cellularity and Eureka and that in-vivo/in-vitro data is soon to be published: they're just finishing up some more experiments.

Clip Backwards:
While not a scientist Andrew, I've certainly been in the industry long enough to know that you can't make any claims of efficacy with under-powered trials like basic Phase 1, dose escalation trials. The reason for this is that there is no scientific basis to do so. And while I may repeat that investors should "follow the science" ad nauseam, I'd actually much rather they follow the "out of my skin" wildly exuberant exaltations I make in these paid-for interviews rather than the (lack of) science I'm required to report via official ASX announcements.


Q. Well-cashed up also?A. That's right, we have well over $100 million in the bank.


Clip Backwards:
Yep that's out of the $225m we've raised from shareholders to date, so executive salaries are sorted for ages!



C'mon, 60c down to 16c, gotta at least get a laugh ...